Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.75 AMA PRA Category 1 CreditsTM.
Physicians should claim only the credit commensurate with their participation in the activity.
This activity is supported by educational grants from Celgene Corporation, Eisai Inc, Genentech, Novartis Pharmaceuticals Corporation, and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
11th Annual International Congress on the Future of Breast Cancer
11th Annual International Congress on the Future of Breast Cancer®
The 11th Annual International Congress on The Future of Breast Cancer®is an educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping, as well as novel agents and strategies changing the future of breast cancer therapy. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be discussed, and controversial issues will be debated. The conference provides a unique opportunity for medical, surgical and radiation oncologists and other healthcare professionals to learn from and interact with international leaders in breast cancer in order to increase knowledge, apply new data to practice, and ultimately improve patient outcomes.
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend.
Incorporate current guidelines and recent data on local therapy, including new strategies for surgical and radiation therapy, into the treatment of patients with breast cancer
Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision-making for breast cancer when appropriate
Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient and tumor characteristics
Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
Select eligible patients with breast cancer for promising clinical trials